Compounds for the treatment of inflammatory disorders

1. A compound represented by Formula (I):

or a pharmaceutically acceptable salt, solvate, ester or isomer thereof, wherein:

ring A is selected from the group consisting of aryl and heteroaryl, each of which is substituted with —Y—R 1 and -Z-R 2 as shown;

X is selected from the group consisting of —S—, —O—, —S(O) 2 —, S(O)—, —(C(R 3 ) 2 ) m — and —N(R 3 )—;

T is alkynyl;

V is selected from the group consisting H, alkyl, cycloalkyl, cycloalkenyl, aryl, heteroaryl, heterocyclyl, and N-oxides of said heteroaryl and heterocyclyl, wherein when each of said cycloalkyl, cycloalkenyl, aryl, heteroaryl, heterocyclyl, and N oxides of said heteroaryl and heterocyclyl contains two radicals on same or adjacent carbon atoms, said radicals may optionally be taken together with the carbon atom(s) to which they are attached to form a five- to eight-membered cycloalkyl, cycloalkenyl, aryl, heterocyclyl or heteroaryl ring, wherein each of the aforementioned cycloalkyl, cycloalkenyl, aryl, heteroaryl, and heterocyclyl, optionally with said five- to eight-membered cycloalkyl, cycloalkenyl, aryl, heterocyclyl, or heteroaryl is independently unsubstituted or substituted with one to four R 10 moieties which can be the same or different;

Y is selected from the group consisting of a covalent bond, —(C(R 4 ) 2 ) n —, —N(R 4 )—, —C(O)N(R 4 )—, —N(R 4 )C(O)—, —N(R 4 )C(O)N(R 4 )—, —S(O) 2 N(R 4 )—, —N(R 4 )—S(O) 2 —, —O—, —S—, —C(O)—, —S(O)—, and —S(O) 2 —;

Z is selected from the group consisting of a covalent bond, —(C(R 4 ) 2 ) n —, —N(R 4 )—, —C(O)N(R 4 )—, —N(R 4 )C(O)—, —N(R 4 )C(O)N(R 4 )—, —S(O) 2 N(R 4 )—, —N(R 4 )—S(O) 2 —, —O—, —S—, —C(O)—, —S(O)—, and —S(O) 2 —;

m is 1 to 3;

n is 1 to 3;

R 1 is selected from the group consisting of H, cyano, alkynyl, halogen, alkyl, cycloalkyl, haloalkyl, aryl, heteroaryl, and heterocyclyl, wherein when each of said cycloalkyl, heterocyclyl, aryl and heteroaryl contains two radicals on adjacent carbon atoms, said radicals may optionally be taken together with the carbon atoms to which they are attached to form a five- to eight-membered cycloalkyl, aryl, heterocyclyl or heteroaryl ring; wherein each of the R 1 alkyl, alkynyl, aryl, heteroaryl, and heterocyclyl, optionally with the five or six-membered cycloalkyl, aryl, heterocyclyl or heteroaryl ring is unsubstituted or optionally independently substituted with one to four R 20 moieties which can be the same or different; with the proviso that when Y is —N(R 4 )—, —S— or —O—, then R 1 is not halogen or cyano;

R 2 is selected from the group consisting of H, cyano, alkynyl, halogen, alkyl, cycloalkyl, haloalkyl, aryl, heteroaryl, and heterocyclyl, wherein when each of said cycloalkyl, heterocyclyl, aryl and heteroaryl contains two radicals on adjacent carbon atoms, said radicals may optionally be taken together with the carbon atoms to which they are attached to form a five- to eight-membered cycloalkyl, aryl, heterocyclyl or heteroaryl ring; wherein each of the R 2 alkyl, cycloalkyl, aryl, heteroaryl, and heterocyclyl, optionally with the five or six-membered cycloalkyl, aryl, heterocyclyl or heteroaryl ring is unsubstituted or optionally independently substituted with one to four R 20 moieties which can be the same or different; with the proviso that when Y is —N(R 4 )—, —S— or —(O)—, then R 2 is not halogen or cyano;

each R 3 is the same of different and is independently selected from the group consisting of H, alkyl, and aryl;

each R 4 is the same or different and is independently selected from the group consisting of H, alkyl, cycloalkyl, haloalkyl, hydroxy, -alkylcycloalkyl, -alkyl-N(alkyl) 2 , heterocyclyl, aryl, and heteroaryl;

R 10 is selected from the group consisting of hydrogen, cyano, nitro, —C(R 4 )═N—OR 4 , —OR 4 , —SR 4 , —N(R 4 ) 2 , —S(O)R 4 , —S(O) 2 R 4 , —N(R 4 )S(O) 2 R 4 , —N(R 4 )—C(O)—R 4 , —C(O)N(R 4 )—S(O) 2 R 4 , —S(O) 2 N(R 4 —C(O)—R 4 , —C(O)N(R 4 )C(O)R 4 , —C(O)N(R 4 )C(O)NR 4 —S(O) 2 N(R 4 ) 2 , —N(R 4 )—C(O)OR 4 , —OC(O)N(R 4 ) 2 , —N(R 4 )C(O)N(R 4 ) 2 , —S(O) 2 N(R 4 ) 2 , —S(O) 2 N(R 4 )—C(O)—R 4 , —N(R 4 )—C(═NR 4 )—N(R 4 ) 2 , —N(R 4 )—C(═N—CN)—N(R 4 ) 2 , -haloalkoxy, —C(O)OR 4 , —C(O)R 4 , —C(O)N(R 4 ) 2 , halogen, alkyl, haloalkyl, aryl, heteroaryl, heterocyclyl, and cycloalkyl, wherein each of the R 10 alkyl, aryl, heteroaryl, heterocyclyl, and cycloalkyl is unsubstituted or optionally independently substituted with one to four R 30 moieties which can be the same or different;

or wherein two R 10 moieties, when attached to the same or adjacent carbon atoms may optionally be taken together with the carbon atom(s) to which they are attached to form a cycloalkyl, cycloalkenyl, heterocyclyl, aryl, or heteroaryl ring;

R 20 is selected from the group consisting of cyano, nitro, —C(R 4 )═N—(O)R 4 , —OR 4 , —SR 4 , —N(R 4 ) 2 , —S(O)R 4 , —S(O) 2 R 4 , —N(R 4 )S(O) 2 R 4 , —N(R 4 )—C(O)—R 4 , —C(O)N(R 4 )—S(O) 2 R 4 , —S(O) 2 N(R 4 )—C(O)—R 4 , —C(O)N(R 4 )C(O)R 4 , —C(O)N(R 4 )C(O)NR 4 —S(O) 2 N(R 4 ) 2 , —N(R 4 )—C(O)OR 4 , —OC(O)N(R 4 ) 2 , —N(R 4 )C(O)N(R 4 ) 2 , —S(O) 2 N(R 4 ) 2 , —S(O) 2 N(R 4 )—C(O)—R 4 , —N(R 4 )—C(═NR 4 )—N(R 4 ) 2 , —N(R 4 )—C(═N—CN)—N(R 4 ) 2 , -haloalkoxy, —C(O)OR 4 , —C(O)R 4 , —C(O)N(R 4 ) 2 , halogen, alkyl, haloalkyl, aryl, heteroaryl, heterocyclyl, and cycloalkyl; wherein when each of said R 20 aryl, heteroaryl, heterocyclyl and cycloalkyl contains two radicals on adjacent carbon atoms, said radicals may optionally be taken together with the carbon atoms to which they are attached to form a five- to eight-membered cycloalkyl, aryl, heterocyclyl or heteroaryl ring; wherein each of said R 20 alkyl, aryl, heteroaryl, heterocyclyl, and cycloalkyl, optionally with said five- to eight-membered cycloalkyl, aryl, heterocyclyl or heteroaryl ring is unsubstituted or substituted with one to four moieties selected independently from the group consisting of alkyl, halo, haloalkyl, hydroxy, alkoxy, haloalkoxy, hydroxyalkyl, cyano, nitro, —NH 2 , —NH(alkyl), and —N(alkyl) 2 ;

or when two R 20 moieties when attached to the same or adjacent carbon atoms may optionally be taken together with the carbon atom(s) to which they are attached to form a cycloalkyl, cycloalkenyl, heterocyclyl, aryl, or heteroaryl ring;

R 30 is selected from the group consisting of cyano, nitro, —C(R 4 )═N—(O)R 4 , —OR 4 , —SR 4 , —N(R 4 ) 2 , —S(O)R 4 , —S(O) 2 R 4 , —N(R 4 )S(O) 2 R 4 , —N(R 4 )—C(O)—R 4 , —C(O)N(R 4 )—S(O) 2 R 4 , —S(O) 2 N(R 4 )—C(O)—R 4 , —C(O)N(R 4 )C(O)R 4 , —C(O)N(R 4 )C(O)NR 4 —S(O) 2 N(R 4 ) 2 , —N(R 4 )—C(O)OR 4 , —OC(O)N(R 4 ) 2 , —N(R 4 )C(O)N(R 4 ) 2 , —S(O) 2 N(R 4 ) 2 , —S(O) 2 N(R 4 )—C(O)—R 4 , —N(R 4 )—C(═NR 4 )—N(R 4 ) 2 , —N(R 4 )—C(═N—CN)—N(R 4 ) 2 , -haloalkoxy, —C(O)OR 4 , —C(O)R 4 , —C(O)N(R 4 ) 2 , halogen, alkyl, haloalkyl, aryl, heteroaryl, heterocyclyl, and cycloalkyl; wherein when each of said R 30 aryl, heteroaryl, heterocyclyl and cycloalkyl contains two radicals on adjacent carbon atoms, said radicals may optionally be taken together with the carbon atoms to which they are attached to form a five- to eight-membered cycloalkyl, aryl, heterocyclyl or heteroaryl ring; wherein each of said R 30 alkyl, aryl, heteroaryl, heterocyclyl, and cycloalkyl, optionally with said five- to eight-membered cycloalkyl, aryl, heterocyclyl or heteroaryl ring is unsubstituted or substituted with one to four moieties selected independently from the group consisting of alkyl, halo, haloalkyl, hydroxy, alkoxy, haloalkoxy, cyano, nitro, —NH 2 , —NH(alkyl), and —N(alkyl) 2 ;

or when two R 30 moieties when attached to the same or adjacent carbon atoms may optionally be taken together with the carbon atom(s) to which they are attached to form a cycloalkyl, cycloalkenyl, heterocyclyl, aryl, or heteroaryl ring.

2. The compound of claim 1 , wherein said isomer is a stereoisomer.

3. The compound of claim 1 , wherein ring A is selected from the group consisting of phenyl, thiophenyl, pyridyl, pyrimidyl, and

each of which is substituted with —Y—R 1 and -Z-R 2 as shown.

4. The compound of claim 3 , wherein said ring A is phenyl which is substituted with —Y—R 1 and -Z-R 2 as shown.

5. The compound of claim 1 , wherein X is selected from the group consisting of —C(R 3 ) 2 ) m — and —N(R 3 )—.

6. The compound of claim 5 , wherein X is —(C(R 3 ) 2 ) m , wherein m is 1 or 2.

7. The compound of claim 6 , wherein m is 1.

8. The compound of claim 1 , wherein R 3 is H.

9. The compound of claim 1 , wherein T is —C≡C—.

10. The compound of claim 1 , wherein V is selected from the group consisting of H, aryl, heteroaryl, and N-oxide of said heteroaryl; wherein when each of the aforementioned aryl, and heteroaryl contains two radicals on same or adjacent carbon atoms, said radicals may optionally be taken together with the carbon atom(s) to which they are attached to form a five or six-membered cycloalkyl, aryl, heterocyclyl or heteroaryl ring; wherein said aryl and heteroaryl optionally with said five or six-membered cycloalkyl, aryl, heterocyclyl or heteroaryl ring is unsubstituted or optionally substituted with one to four R 10 moieties which can be the same or different.

11. The compound of claim 9 , wherein V is selected from the group consisting of phenyl, naphthyl, pyrrolyl, furanyl, thiophenyl, pyrrazolyl, benzopyrazolyl, imidazoly, benzimidazolyl, furazanyl, pyridyl, pyridyl-N-oxide, pyridazinyl, pyrimidinyl, pyrazinyl, indolyl, isoindolyl, indazolyl, indolizinyl, quinolinyl, isopquinolinyl, quinazolinyl, pteridinyl, tetrazolyl, oxazolyl, isothiazolyl, thiazolyl,

each of which is optionally substituted with one or more R 10 moieties such that the number of R 10 moieties per V group does not exceed four.

12. The compound of claim 1 , wherein R 10 is selected from the group consisting of hydrogen, cyano, nitro, —OR 4 , —SR 4 , —N(R 4 ) 2 , —S(O) 2 R 4 —, —S(O) 2 N(R 4 ) 2 , -haloalkoxy, —C(O)OR 4 , —C(O)R 4 , —C(O)N(R 4 ) 2 , —C(O)N(R 4 )—S(O) 2 R 4 , —C(R 4 )═N—OR, halogen, alkyl, haloalkyl, aryl, heteroaryl, and heterocyclyl, wherein each of the alkyl, aryl, heteroaryl, and heterocyclyl is unsubstituted or optionally independently substituted with one to four R 30 moieties which can be the same or different;

or wherein two R 10 moieties, when attached to the same carbon atom are taken together with the carbon atom to which they are attached to form a heterocyclyl ring;

each R 4 is the same or different and is independently selected from the group consisting of H, alkyl, cycloalkyl, haloalkyl, hydroxy, -alkylcycloalkyl, -alkyl-N(alkyl) 2 , heterocyclyl, aryl, and heteroaryl; and

R 30 is selected from the group consisting of halogen, alkyl, haloalkyl, hydroxy, alkoxy, heterocyclyl, —C(R 4 )═N—OR, —(O)-alkyl-cycloalkyl, —N(R 4 ) 2 , and —C(O)N(R 4 ) 2 , wherein said R 30 alkyl is substituted with a —NH 2 .

13. The compound of claim 12 , wherein R 10 is selected from the group consisting of nitro, alkyl, halogen, haloalkyl, haloalkoxy, alkoxy, cyano, —S(O) 2 -alkyl, —NH 2 , —NH(alkyl), —N(alkyl) 2 , cycloalkyl, aryl, heteroaryl, heterocyclyl, -alkyl-heterocyclyl, -cycloalkyl-NH 2 , —S(O) 2 —NH 2 , —S(O) 2 alkyl, —C(O)NH 2 , hydroxy, —C(O)N(H)(cycloalkyl), —C(O)N(H)(alkyl), —N(H)(cycloalkyl), —C(O)O-alkyl, —C(O)OH, —S(O) 2 N(H)(alkyl), —S(O) 2 OH, —S-haloalkyl, —S(O) 2 -haloalkyl, hydroxyalkyl, alkoxyalkyl, —(O)-alkyl-cycloalkyl, -alkyl-O-alkyl-cycloalkyl, —C(O)alkyl, aminoalkyl, -alkyl-NH(alkyl), -alkyl-N(alkyl) 2 , —CH═N—O-alkyl, —C(O)NH-alkyl-N(alkyl) 2 , —C(O)-heterocyclyl, and —NH—C(O)-alkyl, wherein each of said R 10 aryl and heteroaryl is optionally substituted with 1-2 moieties selected from the group consisting of alkyl, —NH 2 , —NH(alkyl), and N(alkyl) 2 ;

or wherein two R 10 moieties attached to the same carbon atom are taken together with the carbon atom to which they are attached to form a heterocyclyl ring.

14. The compound of claim 13 , wherein R 10 is selected from the group consisting of hydrogen, nitro, methyl, fluoro, bromo, trifluoromethyl, chloro, difluoromethoxy, trifluoromethoxy, methoxy, hydroxyl, cyano, —S(O) 2 CH 3 , —NH 2 , isopropyl, cyclopropyl, -cyclopropyl-NH 2 ,

—NH(cyclopropyl), —NH(CH 3 ), —S(O) 2 —NH 2 , —C(O)NH 2 , —C(O)OCH 3 , —C(O)OH, —S(O) 2 N(H)CH 3 , —C(O)NH(CH 3 ), —C(O)NH(cyclopropyl), —S(O) 2 OH, —S—CF 3 , —S(O) 2 —CF 3 , ethoxy, hydroxymethyl, methoxymethyl, isopropoxy, —OCH 2 -cyclopropyl, -CH 2 O—CH 2 -cyclopropyl, —C(O)CH 3 , —C(O)CH 3 , —CH(CH 3 )OH, —CH 2 NH 2 , —CH(CH 3 )NH 2 , —CH 2 NH—CH 3 , —CH(CH 3 )OH, —CH 2 NHCH 3 , —CH═N—OH 3 , —C(CH 3 )═N—OH 3 , —C(O)OCH 2 CH 3 , —C(O)NHCH 2 CH 2 N(CH 3 ) 2 , —NH—C(O)CH 3 ,

or wherein two R 10 moieties, when attached to the same carbon atom are taken together with the carbon atom to which they are attached to form

15. The compound of claim 1 , wherein Y is selected from the group consisting of a covalent bond and —(O)—.

16. The compound of claim 15 , wherein Y is a covalent bond.

17. The compound of claim 15 , wherein Y is —(O)—.

18. The compound of claim 1 , wherein Z is selected from the group consisting of a covalent bond and —(O)—.

19. The compound of claim 18 , wherein Z is —(O)—.

20. The compound of claim 1 , wherein R 1 is selected from the group consisting of hydrogen, cyano, halogen, alkyl, aryl, heteroaryl, haloalkyl, and alkynyl; wherein said R 1 alkyl is unsubstituted or substituted with an aryl, heteroaryl, or heterocyclyl, wherein when said aryl, heteroaryl, or heterocyclyl contains two radicals on adjacent carbon atoms, said radicals may optionally be taken together with the carbon atoms to which they are attached to form a five- to eight-membered cycloalkyl, aryl, heterocyclyl or heteroaryl ring; wherein said aryl, heteroaryl or heterocyclyl substitutent of said R 1 alkyl optionally with said five- to eight-membered cycloalkyl, aryl, heterocyclyl or heteroaryl ring is unsubstituted or optionally independently substituted with one to four R 20 moieties.

21. The compound of claim 1 , wherein R 2 is selected from the group consisting of hydrogen, cyano, halogen, alkyl, aryl, heteroaryl, haloalkyl, and alkynyl; wherein said R 1 alkyl is unsubstituted or substituted with an aryl, heteroaryl, or heterocyclyl, wherein when said aryl, heteroaryl, or heterocyclyl contains two radicals on adjacent carbon atoms, said radicals may optionally be taken together with the carbon atoms to which they are attached to form a five- to eight-membered cycloalkyl, aryl, heterocyclyl or heteroaryl ring; wherein said aryl, heteroaryl or heterocyclyl substitutent of said R 1 alkyl optionally with said five- to eight-membered cycloalkyl, aryl, heterocyclyl or heteroaryl ring is unsubstituted or optionally independently substituted with one to four R 20 moieties.

22. The compound of claim 16 , wherein R 1 is halogen or cyano.

23. The compound of claim 22 , wherein R 1 is fluoro, chloro, or cyano.

24. The compound of claim 17 , wherein R 1 is selected from the group consisting of alkyl, haloalkyl, and alkynyl; wherein said R 1 alkyl is unsubstituted or substituted with a heteroaryl, wherein when said heteroaryl contains two radicals on adjacent carbon atoms, said radicals may optionally be taken together with the carbon atoms to which they are attached to form a five- or six-membered aryl; wherein said heteroaryl substituent of said R 1 alkyl, optionally with said five- or six-membered aryl is substituted with alkyl.

25. The compound of claim 24 , wherein R 1 is selected from the group consisting of CH 3 , —CH 2 —C≡C—CH 3 , difluoromethyl, and

26. The compound of claim 1 , wherein, the compound of Formula (I) is represented by the compound of formula (III):

wherein in formula (III), X is —(CH 2 ) 1-2 —, and T, V, Y, R 1 , and R 3 are as set forth in Formula (I).

27. The compound of claim 26 , wherein X is —CH 2 —.

28. The compound of claim 1 , wherein, the compound of Formula (I) is represented by the compound of formula (IV):

wherein in formula (IV), X is —(CH 2 ) 1-2 —, T, V, Y, R 1 , and R 3 are as set forth in Formula (I).

29. The compound of claim 28 , wherein X is —CH 2 —.

30. A compound selected from the group consisting of

or a pharmaceutically acceptable salt, solvate, or ester thereof.

31. The compound of claim 30 , selected from the group consisting of:

or a pharmaceutically acceptable salt, solvate, or ester thereof.

32. The compound of claim 31 , selected from the group consisting of:

or a pharmaceutically acceptable salt, solvate, or ester thereof.

33. A pharmaceutical composition comprising the compound of claim 1 or a pharmaceutically acceptable salt, solvate or ester thereof, and at least one pharmaceutically acceptable carrier.

34. A pharmaceutical composition comprising at least one compound of claim 30 or a pharmaceutically acceptable salt, solvate or ester thereof, and at least one pharmaceutically acceptable carrier.